Investment firms GV, Northpond Ventures and Sanofi Ventures led a $100m Series B funding round in OMass Therapeutics, a developer of a structural mass spectrometry technology platform, with participation from Syncona, Oxford Science Enterprises and Oxford University. “The completion of this oversubscribed round with such high-calibre investors is recognition of the significance of our OdyssION™ platform and its potential to support the development of an exciting portfolio of novel drug candidates. We have already made significant progress against highly validated but previously ‘undruggable’ targets and can now accelerate them towards clinical development while continuing to expand our pipeline," Ros Deegan, OMass CEO.